Real-World test: does kesimpta® keep MS relapses at bay?
NCT ID NCT06345157
First seen Dec 11, 2025 · Last updated May 15, 2026 · Updated 18 times
Summary
This study looks at how well the drug ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings in Italy. About 379 adults who already started the drug as part of their normal care will be followed for 12 months. The main goal is to see how many relapses occur per year, and researchers will also track thinking speed and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ancona, AN, 60126, Italy
-
Novartis Investigative Site
L’Aquila, AQ, 67100, Italy
-
Novartis Investigative Site
Bari, BA, 70124, Italy
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Chieti, CH, 66100, Italy
-
Novartis Investigative Site
Catania, CT, 95123, Italy
-
Novartis Investigative Site
Catanzaro, CZ, 88100, Italy
-
Novartis Investigative Site
Cona, FE, 44124, Italy
-
Novartis Investigative Site
Foggia, FG, 71122, Italy
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Pozzilli, IS, 86077, Italy
-
Novartis Investigative Site
Monza, MB, 20900, Italy
-
Novartis Investigative Site
Palermo, PA, 90127, Italy
-
Novartis Investigative Site
Pavia, PV, 27100, Italy
-
Novartis Investigative Site
Ravenna, RA, 48100, Italy
-
Novartis Investigative Site
Reggio Calabria, RC, 89124, Italy
-
Novartis Investigative Site
Roma, RM, 00168, Italy
-
Novartis Investigative Site
Roma, RM, 00189, Italy
-
Novartis Investigative Site
Siena, SI, 53100, Italy
-
Novartis Investigative Site
Sassari, SS, 07100, Italy
-
Novartis Investigative Site
Trento, TN, 38122, Italy
-
Novartis Investigative Site
Orbassano, TO, 10043, Italy
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Treviso, TV, 31100, Italy
-
Novartis Investigative Site
Udine, UD, 33100, Italy
-
Novartis Investigative Site
Gallarate, VA, 21013, Italy
-
Novartis Investigative Site
Vicenza, VI, 36100, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Naples, 80138, Italy
-
Novartis Investigative Site
Novara, 28100, Italy
Conditions
Explore the condition pages connected to this study.